Brain Perivascular Macrophages Initiate the Neurovascular Dysfunction of Alzheimer Aβ Peptides

Laibaik Park1, Ken Uekawa2, Lidia Garcia-Bonilla2

  • 1From the Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (L.P., K.U., L.G.B., K.K., M.M., P.Z., J.A., C.I.); McLaughlin Research Institute, Great Falls, MT (R.P., G.C.); and Mayo Clinic Jacksonville, FL (L.Y., S.Y.). lap2003@med.cornell.edu coi2001@med.cornell.edu.

Abstract

Insights

Perivascular macrophages (PVMs) drive Alzheimer disease (AD) neurovascular dysfunction by producing reactive oxygen species. Targeting CD36 and Nox2 in PVMs may offer new therapeutic strategies for AD.

Area of Science:

  • Neuroscience
  • Immunology
  • Vascular Biology

Background:

  • Alzheimer disease (AD) involves cerebral microcirculation dysfunction.
  • Amyloid-beta (Aβ) peptide triggers neurovascular changes via CD36 and Nox2, causing oxidative stress.
  • Brain perivascular macrophages (PVMs) are key in Aβ clearance and produce reactive oxygen species.

Purpose of the Study:

  • To determine if PVMs are the primary source of Aβ-induced reactive oxygen species.
  • To investigate the role of CD36 and Nox2 in PVMs for Aβ's cerebrovascular effects.

Main Methods:

  • Selective PVM depletion using clodronate.
  • Aβ administration (direct cortical, intravascular) and transgenic mouse models (Tg2576).
  • Bone marrow chimeras to assess cell-specific CD36/Nox2 roles.

Main Results:

  • PVM depletion abolished Aβ-induced oxidative stress and vascular dysfunction.
  • CD36 and Nox2 in PVMs are critical for Aβ's deleterious vascular effects.
  • Deleting CD36 or Nox2 from PVMs prevented Aβ-induced dysfunction.

Conclusions:

  • PVMs are a novel effector of Aβ's damaging neurovascular actions.
  • Brain-resident innate immune cells and their receptors contribute to AD pathobiology.
  • Identifies a new mechanism in Alzheimer disease pathogenesis involving PVMs.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.2K